RTRX Retrophin, Inc.

16.98
+0.02  (0%)
Previous Close 16.96
Open 17.04
Price To book 2.15
Market Cap 648.18M
Shares 38,173,000
Volume 406,286
Short Ratio 11.48
Av. Daily Volume 375,556

SEC filingsSee all SEC filings

  1. 8-K/A [Amend] - Current report 17858499
  2. 8-K/A [Amend] - Current report 17858087
  3. 8-K - Current report 17855821
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 17815439
  5. 8-K - Current report 17813951

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 dosing to commence mid-2017.
RE-024
Pantothenate kinase-associated neurodegeneration (PKAN)
NDA filing due 2017
Liquid ursodeoxycholic acid (L-UDCA)
Primary biliary cholangitis (PBC)
Approved Mar 18 2015
Cholbam
Rare Bile Acid Synthesis Disorders
Phase 3 trial protocol to be finalized with FDA 2H 2017, with initiation due thereafter.
Sparsentan
Focal segmental glomerulosclerosis (FSGS)

Latest News

  1. Edited Transcript of RTRX earnings conference call or presentation 4-May-17 8:30pm GMT
  2. Retrophin Announces Presentations for Late-Stage Clinical Development Programs at Upcoming Medical Congresses
  3. Blog Coverage Merck's KEYTRUDA Becomes First Cancer Drug to be Approved by FDA Based on a Common Biomarker Instead of the Location of the Tumor
  4. Retrophin to Present at the Jefferies 2017 Global Healthcare Conference
  5. ETFs with exposure to Retrophin, Inc. : May 12, 2017
  6. Retrophin, Inc. :RTRX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017
  7. Retrophin reports 1Q loss
  8. Retrophin Reports First Quarter 2017 Financial Results
  9. Retrophin, Inc. – Value Analysis (NASDAQ:RTRX) : April 27, 2017
  10. Pharma bro Martin Shkreli asks judge to order document hand-over, bar other evidence
  11. Retrophin, Inc. breached its 50 day moving average in a Bullish Manner : RTRX-US : April 26, 2017
  12. Retrophin to Report First Quarter 2017 Financial Results
  13. Ex-drug executive Shkreli wins separate fraud trial
  14. Retrophin Appoints Ron Squarer to Board of Directors
  15. Bristol-Myers' (BMY) sBLA For Opdivo Accepted by the FDA
  16. Celgene (CELG) Gets Paragraph IV Notice Letter for Pomalyst
  17. Bristol-Myers Announces Data on Immuno-oncology Drug Opdivo
  18. Roche's Rituxan Gets FDA Advisory Committee's Recommendation
  19. Bill Ackman Apologizes for Valeant Investment Error
  20. Acorda Presents Data for Parkinson's Candidate CVT-301

SEC Filings

  1. 8-K/A [Amend] - Current report 17858499
  2. 8-K/A [Amend] - Current report 17858087
  3. 8-K - Current report 17855821
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 17815439
  5. 8-K - Current report 17813951
  6. DEF 14A - Other definitive proxy statements 17761637
  7. 8-K - Current report 17761534
  8. 8-K - Current report 17716109
  9. 8-K - Current report 17675952
  10. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 17655312